Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen

Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen

An over-active alternative complement pathway has been implicated in the pathophysiology of multiple diseases, including IgA nephropathy and geographic atrophy secondary to age related macular degeneration. In first-in-human double-blind, placebo-controlled phase 1 studies, the safety and pharmacody...

Full description

Bibliographic Details
Main Authors: Michael L. McCaleb, Steven G. Hughes, Tamar R. Grossman, Ashley Frazer-Abel, Bill Jung, Lixuan Yin, Scott P. Henry, Brett P. Monia, Eugene Schneider, Richard Geary, Gary T. Brice
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Immunobiology
Subjects:
Complement Alternative Pathway
Antisense oligonucleotides
Complement factor B
Therapeutics
Online Access:http://www.sciencedirect.com/science/article/pii/S0171298525000105

Similar Items

Similar Items